Incannex Healthcare (ASX: IHL) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Incannex Healthcare Chart and Price Data

Fundamentals Data provided by Morningstar.

Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Incannex Healthcare (ASX: IHL)
    Latest News

    A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies
    Share Market News

    Why the Incannex (ASX:IHL) share price is climbing 5% this morning

    The Incannex Healthcare Ltd (ASX: IHL) share price is climbing 5% on the back of a positive update regarding its…

    Read more »

    Young doctor raising arms in air with hands in fists celebrating a new development
    Share Market News

    Here's why the Incannex (ASX:IHL) share price is up 10% today.

    The Incannex (ASX:IHL) share price is flying today after the company's new drug delivered positive results in its latest clinical…

    Read more »

    Medical staff wear hero capes, indicting strong shar [price performace for healthcare shares
    Share Market News

    Up 300% in 1 year, what's driving the Incannex Healthcare (ASX:IHL) share price?

    The Incannex Healthcare share price is up 300% in the past 12 months. Here's a closer look at the company's…

    Read more »

    Young doctor raising arms in air with hands in fists celebrating a new development
    ⏸️ ASX Shares

    Why the Incannex Healthcare (ASX:IHL) share price is up 15% today

    The Incannex Healthcare Limited (ASX: IHL) share price has charged ahead to a 5-year high today. We take a look…

    Read more »

    Share Market News

    Why the Incannex (ASX:IHL) share price is soaring 13%

    The Incannex share price is soaring today as the company mulls a US listing. We take a closer look at…

    Read more »

    Medical staff wear hero capes, indicting strong shar [price performace for healthcare shares
    Share Market News

    The Incannex (ASX:IHL) share price is surging 7% higher today. Here's why

    The Incannex share price is soaring today as the company reported the outcome of its drug trials. We take a…

    Read more »

    Frequently Asked Questions

    Incannex listed on the ASX in May 2007.

    No, Incannex has not yet paid out any dividends.

    IHL ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Incannex Healthcare

    Incannex Healthcare Ltd (ASX: IHL) is a developer of cannabinoid and psychedelic compound medicines. It is currently involved in clinical programs for the treatment of six conditions: Obstructive Sleep Apnea (OSA), Generalised Anxiety Disorder (GAD), traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions.

    The company has an Australian license to import, export, and distribute medicinal cannabis products and has a line of cannabinoid products.

    The Incannex share price hit an all-time high of $5.36 a couple of months after listing in May 2007 before plunging to its current levels.

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    31 Oct 2023 Peter Widdows Buy 230,954 $15,296
    On-market trade. As per announcement on 07-11-2023
    31 Oct 2023 Peter Widdows Buy 280,000 $18,545
    On-market trade.
    02 Jun 2023 Joel Latham Buy 1,583,227 $1,583
    As advised by the company. Purchase of Loyalty Options
    02 Jun 2023 Troy Valentine Buy 2,443,413 $2,443
    As advised by the company. Purchase of Loyalty Options
    02 Jun 2023 Peter Widdows Buy 1,104,913 $1,104
    As advised by the company. Purchase of Loyalty Options

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Troy Robert Valentine Non-Executive ChairmanNon-Executive Director Dec 2017
    Troy Valentine has been Chairman of the Board of Directors since December 2017. Mr. Valentine is a finance professional with managerial and Board experience spanning over 27 years. He commenced his career with Australian brokerage firm Hartley Poynton (now Euroz Hartley s Limited) in 1994 before moving to Patersons Securities (now Canaccord Genuity) in 2000 and subsequently became an Associate Director. During his time at Patersons, he was responsible for managing both retail and institutional accounts. Mr. Valentine has significant corporate and capital raising experience, especially with start-ups and small to mid-cap size companies. He is currently a director of Australian boutique corporate advisory firm Alignment Capital Pty Ltd, which he co-founded in 2014.
    Mr Peter Widdows Non-Executive Director Mar 2018
    Mr Valentine has been Chairman of the Board of Directors since December 2017. Mr. Valentine is a finance professional with managerial and Board experience spanning over 27 years. He commenced his career with Australian brokerage firm Hartley Poynton (now Euroz Hartleys Limited) in 1994 before moving to Patersons Securities (now Canaccord Genuity) in 2000 and subsequently became an Associate Director. During his time at Patersons, he was responsible for managing both retail and institutional accounts. Mr. Valentine has significant corporate and capital raising experience, especially with start-ups and small to mid-cap size companies. He is currently a director of Australian boutique corporate advisory firm Alignment Capital Pty Ltd, which he co-founded in 2014.
    Mr Joel Bradley Latham Chief Executive OfficerExecutive DirectorManaging Director Jul 2018
    Joel Latham is the CEO and Managing Director of Incannex Healthcare and is responsible for the Companys commercial operations, strategic decision- making, and oversight of all clinical development assets. Joel has over 15 years commercial management and executive experience, working for a range multi-national publicly traded companies.
    Dr George Anastassov Non-Executive Director Jun 2022
    Dr Anastassov is responsible for APIRx commercial operations, strategic decision-making, and oversight of all clinical development assets. He is one of the developers of the first-in-the world cannabinoid-containing chewing gum-based delivery system among a number of other systems and formulations. Previously, he was CEO and co-founder of AXIM Biotechnologies, which achieved an all-time-high market capitalization of approximately US$1.2B.
    Mr Lekhram Changoer Non-Executive Director Jun 2022
    --
    Mr Robert Bruce Clark Non-Executive Director Aug 2022
    Mr Clark is a senior-level strategic regulatory affairs expert with over 38 years of US and Global regulatory experience, including >20 years with Pfizer Inc. and >10 years with Novo Nordisk A/S. He is an internationally recognized expert on US Food and Drug Administration ('FDA') and the European Medicines Agency (EMA) liaison interactions, US pharmaceutical advertising practices and regulatory aspects related to healthcare professionals and sales force activities. Mr Clark is Vice President, US Regulatory Affairsfor Novo Nordisk where he provides strategic leadership to a team of over 50 regulatory staff and scientists in the development of new medicines. He advises the global executive team on matters related to drug development programs, FDA liaison strategies, managing FDA-related compliance issues, and monitoring emerging US regulatory trends and opportunities.
    Mr Madhukar (Madhu) Bhalla Company Secretary Jul 2021
    -
    Madhukar (Madhu) Bhalla Company Secretary
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Custody Nominees (Australia) Limited 82,707,741 5.23%
    George Anastassov 66,972,077 4.23%
    Prasch Bv 63,954,841 4.04%
    Dr Sudhanshu Agarwal 34,080,364 2.15%
    Cannvalate Pty Ltd 32,000,000 2.02%
    Mr Raymond Laurence Carroll 30,250,000 1.91%
    J P Morgan Nominees Australia Pty Limited 23,906,440 1.51%
    Brownarrows Pty Ltd <Ejm A/C> 23,610,000 1.49%
    BNP Paribas Noms Pty Ltd Deutsche Bank Tca <Drp> 22,880,950 1.45%
    Citicorp Nominees Pty Limited 19,087,124 1.21%
    Mr Peter Widdows 15,973,694 1.01%
    Mr Kaide Wang 15,700,000 0.99%
    IMI LLC 14,642,234 0.93%
    Bagbo Pty Ltd 14,516,434 0.92%
    Mr Brian Peter Byass 14,247,191 0.90%
    Mr Joel Bradley Latham 13,829,129 0.87%
    Gemini Capitall Llc <The Ars A/C> 13,787,086 0.87%
    Slade Technologies Pty Ltd <Embrey Family S/F A/C> 13,350,000 0.84%
    Alignment Capital Pty Ltd 13,194,248 0.83%
    Ryba Llc 13,090,170 0.83%

    Profile

    since

    Note